Childhood Hepatocellular Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CHL128 MIFTS: 53	Childhood Hepatocellular Carcinoma Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Childhood Hepatocellular Carcinoma

MalaCards integrated aliases for Childhood Hepatocellular Carcinoma:

Name: Childhood Hepatocellular Carcinoma ¹¹ ¹⁹ ¹⁴ ⁷¹

Pediatric Hepatocellular Carcinoma ¹¹ ¹⁹ ⁵⁸ ²⁸ ⁵

Childhood-Onset Hepatocellular Carcinoma ⁵⁸

Childhood Carcinoma of Liver Cell ¹⁹

Pediatric Carcinoma of Liver Cell ¹⁹

Childhood Liver Cell Carcinoma ¹⁹

Pediatric Liver Cell Carcinoma ¹⁹

Childhood Liver Cancer ⁷¹

Childhood-Onset Hcc ⁵⁸

Childhood Hepatoma ¹⁹

Pediatric Hepatoma ¹⁹

Pediatric Hcc ⁵⁸

Characteristics:

Prevelance:

Pediatric Hepatocellular Carcinoma: 1-9/1000000 (Europe) <1/1000000 (United States) ⁵⁸

Age Of Onset:

Pediatric Hepatocellular Carcinoma: Adolescent,Childhood ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Liver diseases Gastrointestinal diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Neoplasms

Malignant neoplasms of digestive organs

Malignant neoplasm of liver and intrahepatic bile ducts

Malignant neoplasm: Liver cell carcinoma

Orphanet: ⁵⁸

Rare hepatic diseases

External Ids:

Disease Ontology ¹¹ DOID:0070322

NCIt ⁴⁹ C7955

ICD10 via Orphanet ³² C22.0

Orphanet ⁵⁸ ORPHA33402

SNOMED-CT via HPO ⁶⁹ 17920008 21522001 248274002 more

UMLS ⁷¹ C0279606 C2945767

Sources

Summaries for Childhood Hepatocellular Carcinoma

GARD: ¹⁹ Childhood hepatocellular carcinoma (childhood HCC) is a rare type of malignant (cancerous) tumor that forms in the cells and tissues of the liver. Childhood HCC is usually found in older children and adolescents (10-14 years), but has been found in children younger than 5. Symptoms may include a mass in the abdomen, a swollen and painful abdomen, weight loss, poor appetite, yellowing of the skin and eyes (jaundice), vomiting, fever, itchy skin, and a decreased number of red blood cells (anemia). The cause of childhood HCC is not well understood; however, underlying disorders that cause liver dysfunction (ex. hepatitis B) and congenital or genetic disorders that affect the liver (ex. tyrosinemia type 1) may increase the risk for childhood HCC to occur.

MalaCards based summary: Childhood Hepatocellular Carcinoma, also known as pediatric hepatocellular carcinoma, is related to fibrolamellar carcinoma and adult hepatocellular carcinoma, and has symptoms including fever, abdominal pain and icterus. An important gene associated with Childhood Hepatocellular Carcinoma is MET (MET Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Signaling by Receptor Tyrosine Kinases and Hepatocyte growth factor receptor signaling. The drugs Amifostine and Sorafenib have been mentioned in the context of this disorder. Affiliated tissues include liver, skin and thyroid, and related phenotypes are hepatomegaly and hepatic fibrosis

Orphanet: ⁵⁸ A rare, aggressive and malignant hepatic tumor arising from the hepatocytes. It develops mainly in children over 10 years of age, either in a cirrhotic background, or more commonly in a non-cirrhotic background (70% of cases).

Disease Ontology: ¹¹ A hepatocellular carcinoma that occurs in children and is characterized by a distinct etiological predisposition, biological behavior, and lower frequency of cirrhosis as compared to adult hepatocellular carcinoma.

Sources

Related Diseases for Childhood Hepatocellular Carcinoma

Diseases related to Childhood Hepatocellular Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 47)

#	Related Disease	Score	Top Affiliating Genes
1	fibrolamellar carcinoma	30.3	LINC01307 CTNNB1 AFP
2	adult hepatocellular carcinoma	30.2	SELENOI CTNNB1 AFP
3	hepatoblastoma	29.9	SLC22A18 MET HGF CTNNB1 AFP
4	cholangiocarcinoma	29.8	MET HGF CTNNB1 AFP
5	liver lipoma	10.2	CTNNB1 AFP
6	testicular fibroma	10.2	CTNNB1 AFP
7	hepatic coma	10.2	HGF AFP
8	hereditary renal cell carcinoma	10.2	MET HGF
9	pancreatoblastoma	10.2	CTNNB1 AFP
10	occipital lobe neoplasm	10.1	TPR MET
11	gastroesophageal adenocarcinoma	10.1	MET HGF
12	hepatitis b	10.1
13	viral hepatitis	10.1
14	liver benign neoplasm	10.1	CTNNB1 AFP
15	gummatous syphilis	10.1	TPR AFP
16	sarcoma, synovial	10.1	MET HGF CTNNB1
17	mesothelioma, malignant	10.0	MET HGF CTNNB1
18	familial renal papillary carcinoma	10.0	TPR MET HGF
19	viral infectious disease	10.0
20	tyrosinemia, type i	10.0
21	rare tumor	10.0
22	gastric adenocarcinoma	9.9	MET CTNNB1 AFP
23	acinar cell carcinoma	9.9	CTNNB1 AFP
24	hepatocellular carcinoma	9.9
25	biliary atresia	9.9
26	hemangioma	9.9
27	liver cirrhosis	9.9
28	tyrosinemia	9.9
29	49, xxxxy syndrome	9.9
30	alagille syndrome 1	9.9
31	cholestasis, progressive familial intrahepatic, 1	9.9
32	factor vii deficiency	9.9
33	alpha-thalassemia/mental retardation syndrome, x-linked	9.9
34	progressive familial intrahepatic cholestasis	9.9
35	non-alcoholic fatty liver disease	9.9
36	cholestasis	9.9
37	intrahepatic cholestasis	9.9
38	bilirubin metabolic disorder	9.9
39	glycogen storage disease	9.9
40	severe combined immunodeficiency	9.9
41	splenomegaly	9.9
42	cryptogenic cirrhosis	9.9
43	familial intrahepatic cholestasis	9.9
44	deafness, autosomal recessive 97	9.8	SEMA6A SEMA3B MET HGF
45	hepatitis	9.8
46	large congenital melanocytic nevus	9.7	HGF FCHSD1
47	renal cell carcinoma, papillary, 1	9.6	TPR SEMA6A SEMA3B MET HGF

Graphical network of the top 20 diseases related to Childhood Hepatocellular Carcinoma:

Sources

Symptoms & Phenotypes for Childhood Hepatocellular Carcinoma

Human phenotypes related to Childhood Hepatocellular Carcinoma:

⁵⁸ ³⁰ (show all 9)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	hepatomegaly ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002240
2	hepatic fibrosis ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001395
3	abdominal pain ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002027
4	elevated alpha-fetoprotein ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0006254
5	vomiting ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002013
6	fatigue ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0012378
7	portal vein thrombosis ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0030242
8	epigastric pain ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0410019
9	hepatic necrosis ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002605

UMLS symptoms related to Childhood Hepatocellular Carcinoma:

fever; abdominal pain; icterus; malaise

Sources

Drugs & Therapeutics for Childhood Hepatocellular Carcinoma

Drugs for Childhood Hepatocellular Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 47)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Amifostine

Approved, Investigational

Phase 3

20537-88-6

2141

Sorafenib

Approved, Investigational

Phase 2, Phase 3

284461-73-0

216239

Carboplatin

Approved

Phase 2, Phase 3

41575-94-4

10339178 38904

Etoposide

Approved

Phase 2, Phase 3

33419-42-0

36462

Irinotecan

Approved, Investigational

Phase 2, Phase 3

97682-44-5, 100286-90-6

60838

Vincristine

Approved, Investigational

Phase 2, Phase 3

2068-78-2, 57-22-7

5978

Picropodophyllin

Approved, Investigational

Phase 2, Phase 3

518-28-5, 477-47-4

10607 72435

Gemcitabine

Approved

Phase 2, Phase 3

95058-81-4, 122111-03-9

60750

Daunorubicin

Approved

Phase 2, Phase 3

20830-81-3

30323

Doxorubicin

Approved, Investigational

Phase 2, Phase 3

23214-92-8

31703

Oxaliplatin

Approved, Investigational

Phase 2, Phase 3

61825-94-3

43805 11947679 6857599

Protective Agents

Phase 3

Radiation-Protective Agents

Phase 3

Anti-Bacterial Agents

Phase 2, Phase 3

Antiviral Agents

Phase 2, Phase 3

Etoposide phosphate

Phase 2, Phase 3

16760419

Anti-Infective Agents

Phase 2, Phase 3

Antimitotic Agents

Phase 2, Phase 3

topoisomerase I inhibitors

Phase 2, Phase 3

Keratolytic Agents

Phase 2, Phase 3

Tubulin Modulators

Phase 2, Phase 3

Antibiotics, Antitubercular

Phase 2, Phase 3

Liposomal doxorubicin

Phase 2, Phase 3

Dermatologic Agents

Phase 2, Phase 3

Levoleucovorin

Approved, Experimental, Investigational

Phase 2

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Trametinib

Approved

Phase 2

871700-17-3

11707110

Capecitabine

Approved, Investigational

Phase 2

154361-50-9

60953

Pembrolizumab

Approved

Phase 2

1374853-91-4

254741536

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 2

59-30-3

6037

D-Tyrosine

Approved, Experimental, Investigational, Nutraceutical

Phase 2

133585-56-5, 60-18-4, 556-02-5

1153 6057

Vitamins

Phase 2

Folate

Phase 2

Vitamin B9

Phase 2

Hormones

Phase 2

Trace Elements

Phase 2

Vitamin B Complex

Phase 2

Antidotes

Phase 2

Calcium, Dietary

Phase 2

Hematinics

Phase 2

Micronutrients

Phase 2

3-Iodobenzylguanidine

Phase 2

Immunoglobulins

Phase 2

Antibodies, Monoclonal

Phase 2

Antibodies

Phase 2

Antineoplastic Agents, Immunological

Phase 2

Calcium

Nutraceutical

Phase 2

7440-70-2

271

Alvocidib

Experimental, Investigational

Phase 1

131740-09-5, 146426-40-6

5466794 5287969

Interventional clinical trials:

(show all 15)

#	Name	Status	NCT ID	Phase	Drugs
1	Intergroup Protocol for Treatment of Children With Hepatoblastoma	Completed	NCT00003994	Phase 3	cisplatin;vincristine sulfate;fluorouracil;amifostine trihydrate;carboplatin
2	Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)	Recruiting	NCT03533582	Phase 2, Phase 3	Carboplatin;Cisplatin;Doxorubicin;Etoposide;Fluorouracil;Gemcitabine;Irinotecan;Oxaliplatin;Sorafenib;Vincristine Sulfate
3	Phase III Randomized Study of Surgical Resection With Versus Without Postoperative Hepatic Arterial Chemotherapy in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombus	Withdrawn	NCT00238160	Phase 3	cisplatin;fluorouracil
4	Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer	Completed	NCT02042443	Phase 2	Capecitabine;Fluorouracil;Leucovorin Calcium;Trametinib
5	A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors	Completed	NCT00091182	Phase 2	oxaliplatin
6	A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma	Completed	NCT01502410	Phase 2	sorafenib tosylate
7	A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors	Completed	NCT00831844	Phase 2
8	The Role of Checkpoint Inhibition in Relapsed/Refractory Pediatric Hepatocellular Carcinoma: Clinical Efficacy and Biologic Correlates - A Phase II Study	Recruiting	NCT04134559	Phase 2	Pembrolizumab
9	A Phase II Study of Imetelstat (GRN163L, NSC# 754228) in Children With Relapsed or Refractory Solid Tumors	Withdrawn	NCT02011126	Phase 2	Imetelstat Sodium
10	A PHASE I STUDY OF FLAVOPIRIDOL (NSC# 649890; IND# 46211) IN PATIENTS WITH RELAPSED OR REFRACTORY PEDIATRIC SOLID TUMORS OR LYMPHOMAS	Completed	NCT00012181	Phase 1	alvocidib
11	Phase I Study of Doxorubicin HCl Liposome in Pediatric Patients With Refractory Solid Tumors	Completed	NCT00019630	Phase 1	doxorubicin HCl liposome
12	A Phase I Study of Oxaliplatin (NSC# 266046, IND #57004) and Irinotecan in Pediatric Patients With Refractory Solid Tumors and Lymphomas	Completed	NCT00101270	Phase 1	irinotecan hydrochloride;oxaliplatin
13	Granzyme B Production as a Biomarker for the Immunomodulatory Activity of Sorafenib in HCC	Completed	NCT02072486		Sorafenib Tosylate
14	Genetics and Biology of Liver Tumorigenesis in Children	Completed	NCT01336881
15	Genetic and Molecular Basis of Pediatric Liver Cancer	Recruiting	NCT03959800

Search NIH Clinical Center for Childhood Hepatocellular Carcinoma

Sources

Genetic Tests for Childhood Hepatocellular Carcinoma

Genetic tests related to Childhood Hepatocellular Carcinoma:

#	Genetic test	Affiliating Genes
1	Pediatric Hepatocellular Carcinoma ²⁸

Sources

Anatomical Context for Childhood Hepatocellular Carcinoma

Organs/tissues related to Childhood Hepatocellular Carcinoma:

MalaCards : Liver, Skin, Thyroid

Sources

Publications for Childhood Hepatocellular Carcinoma

Articles related to Childhood Hepatocellular Carcinoma:

(show top 50) (show all 93)

#	Title	Authors	PMID	Year
1	Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. ⁵	Park WS...Lee JY	9927037	1999
2	Imaging Features of Hepatocellular Carcinoma in Children With and Without Underlying Risk Factors. ⁶²	Rees MA...Khanna G	35544373	2022
3	Histologic type predicts disparate outcomes in pediatric hepatocellular neoplasms: A Pediatric Surgical Oncology Research Collaborative study. ⁶²	Short SS...Riehle KJ	35561331	2022
4	Integrated analysis using ToppMiR uncovers altered miRNA- mRNA regulatory networks in pediatric hepatocellular carcinoma-A pilot study. ⁶²	Whyte SS...Shin S	35859536	2022
5	Second Generation Small Molecule Inhibitors of Gankyrin for the Treatment of Pediatric Liver Cancer. ⁶²	D'Souza AM...Timchenko N	35804840	2022
6	Liver Transplantation for Pediatric Hepatocellular Carcinoma: A Systematic Review. ⁶²	Kakos CD...Alexopoulos SP	35267604	2022
7	Pharmacokinetically guided dosing of oral sorafenib in pediatric hepatocellular carcinoma: A simulation study. ⁶²	Panetta JC...Stewart CF	34060723	2021
8	Transarterial Radioembolization Treatment as a Bridge to Surgical Resection in Pediatric Hepatocellular Carcinoma. ⁶²	Whitlock RS...Kukreja K	33769387	2021
9	C/EBPβ enhances efficacy of sorafenib in hepatoblastoma. ⁶²	Pang C...Li B	33945665	2021
10	Imaging and clinical features of pediatric hepatocellular carcinoma. ⁶²	Arias GA...Chavhan GB	33751174	2021
11	Surgical management of pediatric hepatocellular carcinoma: An analysis of the National Cancer Database. ⁶²	Ziogas IA...Alexopoulos SP	32660779	2021
12	Diagnostic Performance of LI-RADS Version 2018 for Evaluation of Pediatric Hepatocellular Carcinoma. ⁶²	Khanna G...Towbin AJ	33620289	2021
13	Clinical, Pathological and Genetic Characteristics of Pediatric Hepatocellular Carcinoma Associated with Hepatitis B Virus Infection. ⁶²	Zhao P...Li M	34007834	2021
14	Pediatric Hepatocellular Carcinoma. ⁶²	Varol FI	32856229	2020
15	Pediatric Hepatoblastoma, Hepatocellular Carcinoma, and Other Hepatic Neoplasms: Consensus Imaging Recommendations from American College of Radiology Pediatric Liver Reporting and Data System (LI-RADS) Working Group. ⁶²	Schooler GR...Towbin AJ	32602829	2020
16	Sorafenib in pediatric hepatocellular carcinoma from a clinician perspective. ⁶²	Pearson H...Carceller F	32183592	2020
17	Focal Adhesion Kinase (FAK) Over-Expression and Prognostic Implication in Pediatric Hepatocellular Carcinoma. ⁶²	Francalanci P...Alisi A	32806748	2020
18	Clinical heterogeneity of pediatric hepatocellular carcinoma. ⁶²	D'Souza AM...Geller JI	32307899	2020
19	Population-Based Analysis of Hepatocellular Carcinoma in Children: Identifying Optimal Surgical Treatment. ⁶²	Ziogas IA...Alexopoulos SP	32272204	2020
20	Downregulation of SFRP1 is a protumorigenic event in hepatoblastoma and correlates with beta-catenin mutations. ⁶²	Regel I...Kappler R	32189106	2020
21	Hepatoblastoma and Pediatric Hepatocellular Carcinoma: An Update. ⁶²	Ranganathan S...Alaggio R	31554479	2020
22	Hepatitis B Virus Seropositivity Is a Poor Prognostic Factor of Pediatric Hepatocellular Carcinoma: a Population-Based Study in Hong Kong and Singapore. ⁶²	Liu APY...Chiang AKS	33330043	2020
23	Characterization of pediatric hepatocellular carcinoma reveals genomic heterogeneity and diverse signaling pathway activation. ⁶²	Haines K...Lopez-Terrada D	30977242	2019
24	Predisposing Conditions to Pediatric Hepatocellular Carcinoma and Association With Outcomes: Single-center Experience. ⁶²	Cowell E...Miloh T	30676520	2019
25	Is hepatocellular carcinoma the same disease in children and adults? Comparison of histology, molecular background, and treatment in pediatric and adult patients. ⁶²	Weeda VB...Lamers WH	30259629	2019
26	Surgical management of children and adolescents with upfront completely resected hepatocellular carcinoma. ⁶²	D'Souza AM...Geller JI	29968976	2018
27	Orthotopic Liver Transplantation After Stereotactic Body Radiotherapy for Pediatric Hepatocellular Carcinoma with Central Biliary Obstruction and Nodal Involvement. ⁶²	Chen E...Hiniker SM	30648040	2018
28	Pediatric hepatocellular carcinoma. ⁶²	Khanna R...Verma SK	30254403	2018
29	2017 PRETEXT: radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT). ⁶²	Towbin AJ...Tiao GM	29427028	2018
30	Role of interventional radiology in managing pediatric liver tumors : Part 2: percutaneous interventions. ⁶²	Matthew Hawkins C...Lungren MP	29396792	2018
31	Hepatocellular carcinoma in children: hepatic resection and liver transplantation. ⁶²	Angelico R...Spada M	30363724	2018
32	Management of pediatric hepatocellular carcinoma: A multimodal approach. ⁶²	Kohorst MA...Nageswara Rao AA	28631359	2017
33	Stereotactic body radiotherapy for pediatric hepatocellular carcinoma with central biliary obstruction. ⁶²	Hiniker SM...Donaldson SS	28436210	2017
34	Pediatric hepatocellular carcinoma: challenges and solutions. ⁶²	Schmid I...von Schweinitz D	28144610	2017
35	Pediatric hepatocellular carcinoma in a developing country: Is the etiology changing? ⁶²	Palaniappan K...Rela M	27392999	2016
36	Cause and effect: the etiology of pediatric hepatocellular carcinoma and the role for liver transplantation. ⁶²	O'Neill AF...Katzenstein HM	27726261	2016
37	YAP Subcellular Localization and Hippo Pathway Transcriptome Analysis in Pediatric Hepatocellular Carcinoma. ⁶²	LaQuaglia MJ...Vakili K	27605415	2016
38	Hepatocellular Carcinoma in Children: Does Modified Platinum- and Doxorubicin-Based Chemotherapy Increase Tumor Resectability and Change Outcome? Lessons Learned From the SIOPEL 2 and 3 Studies. ⁶²	Murawski M...Czauderna P	26811523	2016
39	Distinct set of chromosomal aberrations in childhood hepatocellular carcinoma is correlated to hepatitis B virus infection. ⁶²	Tan L...Wilkens L	26837720	2016
40	Effects of curcumin in pediatric epithelial liver tumors: inhibition of tumor growth and alpha-fetoprotein in vitro and in vivo involving the NFkappaB- and the beta-catenin pathways. ⁶²	Bortel N...Ellerkamp V	26515460	2015
41	Comparative Analysis and Functional Characterization of HC-AFW1 Hepatocarcinoma Cells: Cytochrome P450 Expression and Induction by Nuclear Receptor Agonists. ⁶²	Braeuning A...Schwarz M	26310804	2015
42	Transarterial embolization for pediatric hepatocellular carcinoma with cardiac cirrhosis. ⁶²	Yamada K...Kaji T	26013052	2015
43	Secular trends were considered in the evaluation of universal hepatitis B vaccination in Taiwan. ⁶²	Chang CH...Tu YK	25660961	2015
44	Anti-tumor activity of sorafenib in a model of a pediatric hepatocellular carcinoma. ⁶²	Nagel C...Fuchs J	25447203	2015
45	Hepatocellular Carcinoma in the Pediatric Population: A Population Based Clinical Outcomes Study Involving 257 Patients from the Surveillance, Epidemiology, and End Result (SEER) Database (1973-2011). ⁶²	Lau CS...Chamberlain RS	26663981	2015
46	Childhood hepatocellular carcinoma: a clinicopathological study of 12 cases with special reference to EpCAM. ⁶²	Zen Y...Hadzic N	24138022	2014
47	Hepatocellular carcinoma in children: epidemiology and the impact of regional lymphadenectomy on surgical outcomes. ⁶²	McAteer JP...Gow KW	24210185	2013
48	Approach to pediatric hepatocellular carcinoma. ⁶²	Walther A...Tiao G	30992867	2013
49	Clinical characteristics and outcome of hepatocellular carcinoma in children and adolescents. ⁶²	Zhang XF...Lv Y	23794023	2013
50	Radioembolisation for treatment of pediatric hepatocellular carcinoma. ⁶²	Hawkins CM...Ristagno R	23212597	2013

Sources

Genes for Childhood Hepatocellular Carcinoma

Genes related to Childhood Hepatocellular Carcinoma (2 elite genes):

(show all 17)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	MET	MET Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	755.35	Pathogenic ⁵ Causative somatic mutation ⁵⁸ DISEASES inferred ¹⁴	9927037
2	CTNNB1	Catenin Beta 1	Protein Coding	29.05	Candidate gene tested ⁵⁸ DISEASES inferred ¹⁴	9927029
3	SELENOI	Selenoprotein I	Protein Coding	6.11	DISEASES inferred ¹⁴
4	HGF	Hepatocyte Growth Factor	Protein Coding	5.4	DISEASES inferred ¹⁴
5	LINC01307	Long Intergenic Non-Protein Coding RNA 1307	RNA Gene	5.21	DISEASES inferred ¹⁴
6	MIR3658	MicroRNA 3658	RNA Gene	4.99	DISEASES inferred ¹⁴
7	SNORD42B	Small Nucleolar RNA, C/D Box 42B	RNA Gene	4.9	DISEASES inferred ¹⁴
8	AFP	Alpha Fetoprotein	Protein Coding	4.73	DISEASES inferred ¹⁴
9	SLC22A18	Solute Carrier Family 22 Member 18	Protein Coding	4.67	DISEASES inferred ¹⁴
10	MUC20	Mucin 20, Cell Surface Associated	Protein Coding	4.44	DISEASES inferred ¹⁴
11	SEMA6A	Semaphorin 6A	Protein Coding	4.39	DISEASES inferred ¹⁴
12	TPR	Translocated Promoter Region, Nuclear Basket Protein	Protein Coding	4.38	DISEASES inferred ¹⁴
13	SEMA3B	Semaphorin 3B	Protein Coding	4.37	DISEASES inferred ¹⁴
14	MIR4698	MicroRNA 4698	RNA Gene	4.35	DISEASES inferred ¹⁴
15	GAB1	GRB2 Associated Binding Protein 1	Protein Coding	4.33	DISEASES inferred ¹⁴
16	FCHSD1	FCH And Double SH3 Domains 1	Protein Coding	4.29	DISEASES inferred ¹⁴
17	MIR514B	MicroRNA 514b	RNA Gene	4.24	DISEASES inferred ¹⁴

Sources

Variations for Childhood Hepatocellular Carcinoma

ClinVar genetic disease variations for Childhood Hepatocellular Carcinoma:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	MET	NM_000245.4(MET):c.3731A>G (p.Lys1244Arg)	SNV	Pathogenic	13890	rs121913677	GRCh37: 7:116423456-116423456 GRCh38: 7:116783402-116783402
2	MET	NM_000245.4(MET):c.3750G>A (p.Met1250Ile)	SNV	Pathogenic	13889	rs121913676	GRCh37: 7:116423475-116423475 GRCh38: 7:116783421-116783421
3	MET	NM_000245.4(MET):c.3518C>T (p.Thr1173Ile)	SNV	Pathogenic	13888	rs121913675	GRCh37: 7:116419007-116419007 GRCh38: 7:116778953-116778953

Cosmic variations for Childhood Hepatocellular Carcinoma:

⁸ (show top 50) (show all 15626)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM97724722	ZXDB	liver,NS,carcinoma,hepatocellular carcinoma	c.1308C>A	p.D436E	23:57593356-57593356	20
2	COSM94430614	ZSWIM1	liver,NS,carcinoma,hepatocellular carcinoma	c.1399A>C	p.S467R	20:45883991-45883991	20
3	COSM94436083	ZSWIM1	liver,NS,carcinoma,hepatocellular carcinoma	c.1399A>C	p.S467R	20:45883991-45883991	20
4	COSM94063771	ZSCAN20	liver,NS,carcinoma,hepatocellular carcinoma	c.2314G>T	p.G772W	1:33494658-33494658	20
5	COSM88264637	ZRSR2	liver,NS,carcinoma,hepatocellular carcinoma	c.304G>T	p.E102*	23:15803788-15803788	20
6	COSM102741209	ZNRF3	liver,NS,carcinoma,hepatocellular carcinoma	c.859A>G	p.M287V	22:29049340-29049340	20
7	COSM131494492	ZNRF3	liver,NS,carcinoma,hepatocellular carcinoma	c.1159A>G	p.M387V	22:29049340-29049340	20
8	COSM103081572	ZNRF3	liver,NS,carcinoma,hepatocellular carcinoma	c.859A>G	p.M287V	22:29049340-29049340	20
9	COSM95977701	ZNFX1	liver,NS,carcinoma,hepatocellular carcinoma	c.2580G>A	p.L860=	20:49257501-49257501	20
10	COSM102131817	ZNFX1	liver,NS,carcinoma,hepatocellular carcinoma	c.2580G>A	p.L860=	20:49257501-49257501	20
11	COSM95960776	ZNFX1	liver,NS,carcinoma,hepatocellular carcinoma	c.2580G>A	p.L860=	20:49257501-49257501	20
12	COSM113317148	ZNF853	liver,NS,carcinoma,hepatocellular carcinoma	c.1610G>T	p.G537V	7:6622601-6622601	20
13	COSM99592496	ZNF829	liver,NS,carcinoma,hepatocellular carcinoma	c.829T>A	p.F277I	19:36891962-36891962	20
14	COSM128686611	ZNF829	liver,NS,carcinoma,hepatocellular carcinoma	c.1072T>A	p.F358I	19:36891962-36891962	20
15	COSM123358576	ZNF827	liver,NS,carcinoma,hepatocellular carcinoma	c.691C>T	p.L231=	4:145885684-145885684	20
16	COSM123949383	ZNF827	liver,NS,carcinoma,hepatocellular carcinoma	c.1741C>T	p.L581=	4:145885684-145885684	20
17	COSM101741672	ZNF827	liver,NS,carcinoma,hepatocellular carcinoma	c.1741C>T	p.L581=	4:145885684-145885684	20
18	COSM86004822	ZNF653	liver,NS,carcinoma,hepatocellular carcinoma	c.1553A>C	p.H518P	19:11485673-11485673	20
19	COSM98561269	ZNF615	liver,NS,carcinoma,hepatocellular carcinoma	c.141G>A	p.V47=	19:52002156-52002156	20
20	COSM142353152	ZNF615	liver,NS,carcinoma,hepatocellular carcinoma	c.141G>A	p.V47=	19:52002156-52002156	20
21	COSM142221290	ZNF615	liver,NS,carcinoma,hepatocellular carcinoma	c.141G>A	p.V47=	19:52002156-52002156	20
22	COSM99854658	ZNF615	liver,NS,carcinoma,hepatocellular carcinoma	c.156G>A	p.V52=	19:52002156-52002156	20
23	COSM139729931	ZNF615	liver,NS,carcinoma,hepatocellular carcinoma	c.141G>A	p.V47=	19:52002156-52002156	20
24	COSM141470046	ZNF615	liver,NS,carcinoma,hepatocellular carcinoma	c.141G>A	p.V47=	19:52002156-52002156	20
25	COSM141819438	ZNF615	liver,NS,carcinoma,hepatocellular carcinoma	c.141G>A	p.V47=	19:52002156-52002156	20
26	COSM145038099	ZNF615	liver,NS,carcinoma,hepatocellular carcinoma	c.141G>A	p.V47=	19:52002156-52002156	20
27	COSM91868668	ZNF536	liver,NS,carcinoma,hepatocellular carcinoma	c.3900G>T	p.K1300N	19:30557161-30557161	20
28	COSM91880764	ZNF536	liver,NS,carcinoma,hepatocellular carcinoma	c.2171-78T>G	p.?	19:30534769-30534769	20
29	COSM140721836	ZNF521	liver,NS,carcinoma,hepatocellular carcinoma	c.2998+205G>A	p.?	18:25194955-25194955	20
30	COSM131506983	ZNF521	liver,NS,carcinoma,hepatocellular carcinoma	c.3658+205G>A	p.?	18:25194955-25194955	20
31	COSM94799980	ZNF521	liver,NS,carcinoma,hepatocellular carcinoma	c.3658+205G>A	p.?	18:25194955-25194955	20
32	COSM90582798	ZNF518B	liver,NS,carcinoma,hepatocellular carcinoma	c.1624G>T	p.E542*	4:10444705-10444705	20
33	COSM87577038	ZNF462	liver,NS,carcinoma,hepatocellular carcinoma	c.6715G>T	p.V2239L	9:106974156-106974156	20
34	COSM109096265	ZNF462	liver,NS,carcinoma,hepatocellular carcinoma	c.3433G>T	p.V1145L	9:106974156-106974156	20
35	COSM104985080	ZNF385B	liver,NS,carcinoma,hepatocellular carcinoma	c.298+23785G>T	p.?	2:179745718-179745718	20
36	COSM104427909	ZNF385B	liver,NS,carcinoma,hepatocellular carcinoma	c.20G>T	p.S7I	2:179745718-179745718	20
37	COSM151538615	ZNF385B	liver,NS,carcinoma,hepatocellular carcinoma	c.253+23785G>T	p.?	2:179745718-179745718	20
38	COSM127708351	ZNF345	liver,NS,carcinoma,hepatocellular carcinoma	c.47-856A>T	p.?	19:36891962-36891962	20
39	COSM135887725	ZNF276	liver,NS,carcinoma,hepatocellular carcinoma	c.1168C>G	p.L390V	16:89734008-89734008	20
40	COSM84511025	ZNF276	liver,NS,carcinoma,hepatocellular carcinoma	c.1219C>G	p.L407V	16:89734008-89734008	20
41	COSM111609487	ZNF276	liver,NS,carcinoma,hepatocellular carcinoma	c.1444C>G	p.L482V	16:89734008-89734008	20
42	COSM92353291	ZNF26	liver,NS,carcinoma,hepatocellular carcinoma	c.1010C>T	p.T337I	12:133010889-133010889	20
43	COSM130415812	ZNF26	liver,NS,carcinoma,hepatocellular carcinoma	c.950C>T	p.T317I	12:133010889-133010889	20
44	COSM88697750	ZNF217	liver,NS,carcinoma,hepatocellular carcinoma	c.*194A>T	p.?	20:53569094-53569094	20
45	COSM95253159	ZNF217	liver,NS,carcinoma,hepatocellular carcinoma	c.*194A>T	p.?	20:53569094-53569094	20
46	COSM94505616	ZMYND12	liver,NS,carcinoma,hepatocellular carcinoma	c.425-1G>T	p.?	1:42440026-42440026	20
47	COSM89943752	ZMYM4	liver,NS,carcinoma,hepatocellular carcinoma	c.86-8201G>T	p.?	1:35350724-35350724	20
48	COSM101398456	ZIC2	liver,NS,carcinoma,hepatocellular carcinoma	c.-18C>T	p.?	13:99982047-99982047	20
49	COSM113521587	ZGPAT	liver,NS,carcinoma,hepatocellular carcinoma	c.*197C>A	p.?	20:63736116-63736116	20
50	COSM94679661	ZGPAT	liver,NS,carcinoma,hepatocellular carcinoma	c.*197C>A	p.?	20:63736116-63736116	20

Sources

Expression for Childhood Hepatocellular Carcinoma

Search GEO for disease gene expression data for Childhood Hepatocellular Carcinoma.

Sources

Pathways for Childhood Hepatocellular Carcinoma

Pathways related to Childhood Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

(show all 15)

#	Super pathways	Score	Top Affiliating Genes
1	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.52	CTNNB1 GAB1 HGF MET MUC20
2	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.19	MET HGF GAB1 CTNNB1
3	MET promotes cell motility ⁶⁶ Show member pathways Beta1 integrin cell surface interactions ⁶¹ MET activates PTK2 signaling ⁶⁶ MET activates RAP1 and RAC1 ⁶⁶ MET activates RAS signaling ⁶⁶ MET interacts with TNS proteins ⁶⁶ MET Receptor Activation ⁶⁶ MET receptor recycling ⁶⁶ Signaling by MET ⁶⁶	12.14	MUC20 MET HGF GAB1
4	Integrin-mediated cell adhesion ⁷⁴ Show member pathways HGF Pathway ⁶⁴	12	MET HGF GAB1
5	Remodeling of Adherens Junctions ⁶⁴	11.79	MET HGF CTNNB1
6	Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers ⁶⁵	11.79	MET HGF AFP
7	Direct p53 effectors ⁶¹	11.76	MET HGF AFP
8	Listeria monocytogenes entry into host cells ⁶⁶ Show member pathways E-cadherin signaling events ⁶¹ InlA-mediated entry of Listeria monocytogenes into host cells ⁶⁶ InlB-mediated entry of Listeria monocytogenes into host cell ⁶⁶ Negative regulation of MET activity ⁶⁶	11.37	MET HGF CTNNB1
9	FGF signaling pathway ⁶¹	11.23	MET HGF GAB1
10	Signaling events mediated by TCPTP ⁶¹ Show member pathways MET activates PI3K/AKT signaling ⁶⁶	11.09	MET HGF GAB1
11	Arf6 signaling events ⁶¹	11.04	MET HGF
12	Syndecan-1-mediated signaling events ⁶¹	11	MET HGF
13	Stabilization and expansion of the E-cadherin adherens junction ⁶¹	10.96	MET HGF CTNNB1
14	Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ⁶¹	10.87	MUC20 MET HGF GAB1 CTNNB1
15	Extracellular vesicle-mediated signaling in recipient cells ⁷⁴	10.58	MET HGF CTNNB1

Sources

GO Terms for Childhood Hepatocellular Carcinoma

Biological processes related to Childhood Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	myoblast proliferation	GO:0051450	9.56	HGF CTNNB1
2	negative regulation of hydrogen peroxide-mediated programmed cell death	GO:1901299	9.46	MET HGF
3	semaphorin-plexin signaling pathway	GO:0071526	9.43	SEMA6A SEMA3B MET
4	hepatocyte growth factor receptor signaling pathway	GO:0048012	9.1	MUC20 MET HGF